Therapeutic trial for infant acute lymphoblastic leukemia: The pediatric oncology group experience (POG 8493)

American Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 1, 1997, Pages 35-42

  Frankel, Lawrence S ^a   Ochs, J ^b   Shuster, J J ^c   Dubowy, R ^d   Bowman, W P ^e   Hockenberry Eaton, M ^f   Borowitz, M ^g   Carroll, A J ^h   Steuber, C P ^f   Pullen, D J ⁱ  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^c University of Florida ^*  (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^e Risk Evaluation to Achieve Cardiovascular Health   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Acute lymphocytic leukemia of childhood; Infant leukemia; Therapy of leukemia in infants

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMMUNOTOXICITY; INFANT; INFANT DISEASE; INFECTION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031003109     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199701000-00005     Document Type: Article

References (25)

1. Vietti TJ, Land V, Shuster JJ, et al. Progress against childhood cancer: the Pediatric Oncology Group Experience. Pediatrics 1992; 89: 597-600.
2. Crist W, Pullen J, Boyett J, et al. Clinical and biologic features predict a poor prognosis in acute lymphoid leukemia in infants: a Pediatric Oncology Group Study. Blood 1986; 67: 135-40.
3. Borowitz MJ, Carroll AJ, Shuster JJ, et al. Use of clinical and laboratory features to define prognostic subgroups in B-precusor ALL. Experience of the Pediatric Oncology Group. In: Recent results in cancer research, vol. 131. Heidelberg: Thiele-Springer, 1993: 257-69.
4. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 1985; 65: 21-31.
5. Nagasaka M, Maeda S, Maeda H, et al. Four cases of t(4: 11) acute leukemia and its myelomonocytic nature in infants. Blood 1983; 61: 1174-81.
6. Cangir A, George S, Sullivan MP. Unfavorable prognosis of acute leukemia in infancy. Cancer 1975; 36: 1973-8.
7. 9/L. J Clin Oncol 1987; 5: 1015-21.
8. Pullen DJ, Falletta JM, Crist WM, et al. Southwest Oncology Group experience with immunologic phenotyping in acute lymphocytic in childhood. Cancer Res 1981; 41: 4802.
9. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukemias. Br J Hematol 1976; 33: 451.
10. Carroll AJ, Castleberry RP, Crist WM. Lack of association between abnormalities of the chromosome 9 short arm and either 91ymphomatous9 features or T cell phenotype in childhood acute lymphocytic leukemia. Blood 1987; 69: 735-8.
11. Morgan E, Baum E, Breslow N, Takashima J, D’Angio G. Chemotherapy-related toxicity in infants treated according to the Second National Wilms’ Tumor Study. J Clin Oncol 1988; 6: 51-5.
12. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J Royal Stat Soc A 1972; 135: 185-98.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
14. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
15. Reaman G, Zeltzer P, Bleyer WA, et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children’s Cancer Study Group. J Clin Oncol 1985; 3: 1513-21.
16. Derluska DR, Rokicka-Milewska R, Lewicki Z, et al. Acute lymphoblastic leukemia in children below two years of age. Acta Haematol Pol 1990; 21: 1-9.
17. Ishii E, Okamura J, Tsuchida M, et al. Infant leukemia in Japan: clinical and biological analysis of 48 cases. Med Pediatr Oncol 1991; 19: 28-32.
18. Jackson JF, Boyett J, Pullen J, et al. Favorable prognosis associated with hyperdiploidy in children with acute lymphocytic leukemia correlates with extra chromosome 6. Cancer 1990; 66: 1183-9.
19. Reaman GH, Steinherz PG, Gaynon PS, et al. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Cancer Treat Rep 1987; 71: 1033-8.
20. Stark B, Vogel R, Cohen IJ, et al. Biologic and cytogenetic characteristics of leukemia in infants. Cancer 1989; 63: 117-25.
21. Pullen J, Boyett J, Shuster JJ, et al. Extended triple intrathecal chemotherapy provides effective central nervous system preventative therapy for patients with B-progenitor acute lymphoblastic leukemia. J Clin Oncol 1993; 11: 839-49.
22. Miller DR, Baehner RL, Miller LP. Blood diseases of infancy and childhood. 6th ed. 1990.
23. Pui C-H, Frankel L, Carroll AJ, et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4: 11)(q21;q23): a collaborative study of 40 cases. Blood 1991; 77: 440-7.
24. Hays T, Morse HG, Crouse VL, Odom LF. Treatment of t(4;11) acute leukemia with aggressive multiagene chemotherapy. Am J Pediatr Hematol Oncol 1989; 11: 16-9.
25. Chen C-S, Sorenson PHB, Domer PH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcomes. Blood 1993; 81: 2386-93.